Unraveling the role of M1 macrophage and CXCL9 in predicting immune checkpoint inhibitor efficacy through multicohort analysis and single-cell RNA sequencing

Abstract

The exact function of M1 macrophages and CXCL9 in forecasting the effectiveness of immune checkpoint inhibitors (ICIs) is still not thoroughly investigated. We investigated the potential of M1 macrophage and C-X-C Motif Chemokine Ligand 9 (CXCL9) as predictive markers for ICI efficacy, employing a comprehensive approach integrating multicohort analysis and single-cell RNA sequencing. A significant correlation between high M1 macrophage and improved overall survival (OS) and objective response rate (ORR) was found. M1 macrophage expression was most pronounced in the immune-inflamed phenotype, aligning with increased expression of immune checkpoints. Furthermore, CXCL9 was identified as a key marker gene that positively correlated with M1 macrophage and response to ICIs, while also exhibiting associations with immune-related pathways and immune cell infiltration. Additionally, through exploring RNA epigenetic modifications, we identified Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3G (APOBEC3G) as linked to ICI response, with high expression correlating with improved OS and immune-related pathways. Moreover, a novel model based on M1 macrophage, CXCL9, and APOBEC3G-related genes was developed using multi-level attention graph neural network, which showed promising predictive ability for ORR. This study illuminates the pivotal contributions of M1 macrophages and CXCL9 in shaping an immune-active microenvironment, correlating with enhanced ICI efficacy. The combination of M1 macrophage, CXCL9, and APOBEC3G provides a novel model for predicting clinical outcomes of ICI therapy, facilitating personalized immunotherapy.

Keywords

Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3G (APOBEC3G) / C-X-C Motif Chemokine Ligand 9 (CXCL9) / immune checkpoint inhibitors / M1 macrophage / multi-level attention graph neural network / tumor immune microenvironment

References

1	A Ribas, JD Wolchok. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-1355.
2	H Raskov, A Orhan, JP Christensen, I Gogenur. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124(2):359-367.
3	J Zhang, D Huang, PE Saw, E Song. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol. 2022;43(7):523-545.
4	L Cassetta, JW Pollard. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887-904.
5	A Mantovani, P Allavena, F Marchesi, C Garlanda. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21(11):799-820.
6	MJ Pittet, O Michielin, D Migliorini. Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 2022;19(6):402-421.
7	DG DeNardo, B Ruffell. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19(6):369-382.
8	D Zeng, Z Ye, J Wu, et al. Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer. Theranostics. 2020;10(15):7002-7014.
9	IG House, P Savas, J Lai, et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res. 2020;26(2):487-504.
10	MT Chow, AJ Ozga, RL Servis, et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity. 2019;50(6):1498-1512. e1495.
11	F Markl, D Huynh, S Endres, S Kobold. Utilizing chemokines in cancer immunotherapy. Trends Cancer. 2022;8(8):670-682.
12	PM Marcovecchio, G Thomas, S Salek-Ardakani. CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer. J Immunother Cancer. 2021;9(2):e002045.
13	D Dangaj, M Bruand, AJ Grimm, et al. Cooperation between constitutive and inducible chemokines enables t cell engraftment and immune attack in solid tumors. Cancer Cell. 2019;35(6):885-900. e810.
14	Y Qu, J Wen, G Thomas, et al. Baseline frequency of inflammatory Cxcl9-expressing tumor-associated macrophages predicts response to avelumab treatment. Cell Rep. 2020;32(1):107873.
15	EM Garrido-Martin, TWP Mellows, J Clarke, et al. M1(hot) tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer. J Immunother Cancer. 2020;8(2):e000778.
16	H Yin, X Zhang, P Yang, et al. RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming. Nat Commun. 2021;12(1):1394.
17	DS Chen, I Mellman. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321-330.
18	Y Yu, W Zhang, A Li, et al. Association of long noncoding RNA biomarkers with clinical immune subtype and prediction of immunotherapy response in patients with cancer. JAMA Netw Open. 2020;3(4):e202149.
19	V Piccolo, A Curina, M Genua, et al. Opposing macrophage polarization programs show extensive epigenomic and transcriptional cross-talk. Nat Immunol. 2017;18(5):530-540.
20	NR Anderson, NG Minutolo, S Gill, M Klichinsky. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 2021;81(5):1201-1208.
21	H Xiong, S Mittman, R Rodriguez, et al. Anti-PD-L1 treatment results in functional remodeling of the macrophage compartment. Cancer Res. 2019;79(7):1493-1506.
22	R Tokunaga, W Zhang, M Naseem, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation—a target for novel cancer therapy. Cancer Treat Rev. 2018;63:40-47.
23	E Humblin, AO Kamphorst. CXCR3-CXCL9: it's all in the tumor. Immunity. 2019;50(6):1347-1349.
24	K Butler, AR Banday. APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential. J Hematol Oncol. 2023;16(1):31.
25	S Venkatesan, M Angelova, C Puttick, et al. Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution. Cancer Discov. 2021;11(10):2456-2473.
26	M Petljak, AM Green, J Maciejowski, MD Weitzman. Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer. Nat Genet. 2022;54(11):1599-1608.
27	B Leonard, GJ Starrett, MJ Maurer, et al. APOBEC3G expression correlates with T-cell infiltration and improved clinical outcomes in high-grade serous ovarian carcinoma. Clin Cancer Res. 2016;22(18):4746-4755.
28	K Krug, EJ Jaehnig, S Satpathy, et al. Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy. Cell. 2020;183(5):1436-1456. e1431.
29	T Peng, B Liu, S Lin, et al. APOBEC3G expression correlates with unfavorable prognosis and immune infiltration in kidney renal clear cell carcinoma. Heliyon. 2022;8(12):e12191.
30	S Mariathasan, SJ Turley, D Nickles, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544-548.
31	TL Rose, WH Weir, GM Mayhew, et al. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br J Cancer. 2021;125(9):1251-1260.
32	CL Hsu, DL Ou, LY Bai, et al. Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma. Liver Cancer. 2021;10(4):346-359.
33	JP Foy, A Karabajakian, S Ortiz-Cuaran, et al. Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients. Eur J Cancer. 2022;174:287-298.
34	B Chen, MS Khodadoust, CL Liu, AM Newman, AA Alizadeh. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243-259.
35	MI Love, W Huber, S Anders. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
36	G Yu, LG Wang, Y Han, QY He. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284-287.
37	D Szklarczyk, AL Gable, D Lyon, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607-D613.
38	D Warde-Farley, SL Donaldson, O Comes, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38:W214-W220.
39	A Kechin, U Boyarskikh, A Kel, M Filipenko. cutPrimers: a new tool for accurate cutting of primers from reads of targeted next generation sequencing. J Comput Biol. 2017;24(11):1138-1143.
40	A Dobin, CA Davis, F Schlesinger, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21.
41	Y Liao, GK Smyth, W Shi. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30(7):923-930.
42	R Satija, JA Farrell, D Gennert, AF Schier, A Regev. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33(5):495-502.
43	I Korsunsky, N Millard, J Fan, et al. Fast, sensitive and accurate integration of single-cell data with harmony. Nat Methods. 2019;16(12):1289-1296.
44	X Xing, F Yang, H Li, et al. Multi-level attention graph neural network for clinically interpretable pathway-level biomarkers discovery. bioRxiv. 2020:2020.2012. 2003.409755.